Evidence map›Paper›PMID 42642696›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

In vitro activity of aztreonam-avibactam against carbapenem-resistant Pseudomonas aeruginosa from Southern Brazil.

Gabriela da Silva Collar, Natália Kehl Moreira, Patrícia Orlandi Barth, Maria do Carmo Fontourac Pereira, Afonso Luís Barth, Juliana Caierão

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gabriela da Silva CollarLaboratório de Pesquisa em Bacteriologia Clínica (LaBaC), Universidade Federal do Rio Grande do Sul, Avenida Ipiranga, 2752, Laboratory 605A, Azenha District, Porto Alegre, 90610-000, RS, Brazil. gabi.collar@gmail.com.ORCID http://orcid.org/0000-0003-2819-0769
Natália Kehl MoreiraLaboratório de Pesquisa em Bacteriologia Clínica (LaBaC), Universidade Federal do Rio Grande do Sul, Avenida Ipiranga, 2752, Laboratory 605A, Azenha District, Porto Alegre, 90610-000, RS, Brazil.
Patrícia Orlandi BarthLaboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Maria do Carmo Fontourac PereiraHospital Nossa Senhora da Conceição, Grupo Hospitalar Conceição, Porto Alegre, Brazil.
Afonso Luís BarthPrograma de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Juliana CaierãoLaboratório de Pesquisa em Bacteriologia Clínica (LaBaC), Universidade Federal do Rio Grande do Sul, Avenida Ipiranga, 2752, Laboratory 605A, Azenha District, Porto Alegre, 90610-000, RS, Brazil.ORCID http://orcid.org/0000-0002-8776-8447

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem-resistant Pseudomonas aeruginosa (CR-PA) has limited therapeutic options, particularly when metallo-β-lactamases are present. We evaluated aztreonam-avibactam (AZA) against 48 clinical P. aeruginosa isolates, including 44 CR-PA with 18 difficult-to-treat resistant isolates. Class B carbapenemase genes were present in 50.0%, mainly bla

Indexed as

Aztreonam-avibactamCeftazidime-avibactamMetallo-β-lactamaseNDMPseudomonas aeruginosa

Identifiers

PMID42642696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.